Formulary restrictions can create treatment barriers for patients with atrial fibrillation, including unnecessary delays in treatment and prescription abandonment, with vulnerable populations at greater risk.
Dionne M. Hines, PhD, MPH
Advertisement
Articles by Dionne M. Hines, PhD, MPH
Advertisement
Latest Updated Articles
Journey to Anticoagulant Access Following Payer Rejection of ApixabanPublished: November 7th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
2
Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps
3
Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD
4
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
5